Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide Impact Assessment
NCT07740291Recruiting
- Sponsor
- Texas Tech University
- Start
- Jan 2025
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Open-label trial of tirzepatide and semaglutide in obesity and Overweight (2 arms), sponsored by Texas Tech University. Primary endpoints: Change in Fasting Blood Glucose at 3 months, Change in LDL Cholesterol at 3 months and 11 more. Started Jan 2025; status: recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07740291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07740291.